Pelareorep is under clinical development by Oncolytics Biotech and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Pelareorep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pelareorep (Reolysin) is under development for the treatment of metastatic breast cancer, HER2- breast cancer, relapsed or refractory multiple myeloma, acute myelocytic leukemia, metastatic colorectal cancer, metastatic triple negative breast cancer, metastatic pancreatic cancer, metastatic colorectal cancer, unresectable anal cancer and glioblastoma multiforme. The drug candidate is administered as injection or infusion through intravenous, intralesional, intratumoral, intraperitoneal and intrathecal route. Reolysin is a formulation of the human reovirus. It is reovirus type 3 without transgenes. The drug candidate was under development for the treatment of Ewing sarcoma, malignant fibrous histiocytoma, osteosarcoma, soft tissue sarcoma, fibrosarcoma, leiomyosarcoma, metastatic squamous cell carcinoma of the head and neck, recurrent and refractory astrocytoma, oligodendroglioma, high grade gliomas, medulloblastoma, primitive neuroectodermal tumor (PNET), gastric cancer, metastatic hormone-refractory prostate cancer and muscle-invasive bladder cancer, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC), metastatic adenocarcinoma of the pancreas, hepatocellular carcinoma and metastatic melanoma.
Oncolytics Biotech overview
Oncolytics Biotech is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company’s lead product candidate, pelareorep, is an unmodified reovirus that is an intraosseous (I-O) viral agent indicated for systemic administration for the treatment of hematological malignancies and solid tumors. The company is advancing pelareorep as a combination with other products in various clinical phases for the treatment of metastatic breast cancer (BC), early-stage BC, pancreatic cancer, and relapsed or refractory multiple myeloma. Oncolytics Biotech is headquartered in Calgary, Alberta, Canada.
For a complete picture of Pelareorep’s drug-specific PTSR and LoA scores, buy the report here.